Intech Biopharm (ROCO:6461) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6461 Intech Biopharm Ltd ROCO:6461
55 GF Score
Price NT$15.45
GF Value NT$87.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Intech Biopharm FFO?

FFO (Funds from operations) only applies to REITs.

ROCO:6461
55GF Score
Intech Biopharm Ltd ROCO:6461
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Intech Biopharm (ROCO:6461) Overvalued in 2026?

Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued. The current stock price of NT$15.45 is trading 82.4% below its estimated GF Value™ of NT$87.90. GuruFocus considers Intech Biopharm to be Possible Value Trap.

Key valuation signals for ROCO:6461:

  • FFO:
  • GF Value™: NT$87.90 vs. price of NT$15.45 (82.4% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intech Biopharm Business Description

Address No.36, Ruiguang Road, 3rd Floor, Lane 358, Neihu District, Taipei, TWN, 114
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
55GF Score

Get the complete analysis for ROCO:6461

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.45
Price
NT$87.90
GF Value